Invectys well poised to bring its anti-HLA-G CAR-T cells to clinical trials …
Invectys Strengthens Advisory Board with the Appointment of Dennis J. Purcell, Life Sciences Industry Veteran and Founder of Aisling Capital LLC Paris, France, May…
Invectys publishes positive clinical results for its INVAC-1 Phase I Study in Clinical Cancer Research With an extended Phase I and a new delivery method…
Invectys focuses on the development of innovative anti-cancer therapeutic approaches in immunotherapy. It is backed by French and international private investors…
Invectys élu « meilleur projet – jeune entreprise » 2019 par le Board international de MATWIN Invectys, société biopharmaceutique développant des thérapies…
Invectys will attend to the 18th annual BIO€QUITY Europe Meet Invectys there ! More information: invest@invectys.com 18TH ANNUAL BIO€QUITY EUROPE Bio€quity…
BIO-Europe Spring 2019 March 25th – 27th 2019 Messe Wien Exhibition and Congress Center, Vienna, Austria Invectys will be attending the BIO-Europe Spring 2019.…
Invectys will be attending the AACR Annual Meeting 2019, March 29 – Apr 3, 2019. Georgia World Congress Center Atlanta, The AACR (American Association for…
